Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Sei Investments Co. acquired a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,802 shares of the company’s stock, valued at approximately $49,000.

Several other institutional investors and hedge funds have also recently modified their holdings of BDTX. Intech Investment Management LLC boosted its holdings in Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after buying an additional 6,340 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Black Diamond Therapeutics during the fourth quarter worth about $42,000. Raymond James Financial Inc. bought a new position in Black Diamond Therapeutics in the 4th quarter worth approximately $53,000. SLT Holdings LLC purchased a new stake in Black Diamond Therapeutics during the 4th quarter valued at approximately $66,000. Finally, Rhumbline Advisers increased its holdings in Black Diamond Therapeutics by 14.9% in the 4th quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock valued at $120,000 after acquiring an additional 7,290 shares during the last quarter. 95.47% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BDTX has been the subject of a number of recent research reports. HC Wainwright raised their target price on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday, March 19th. Finally, Stifel Nicolaus lowered their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Black Diamond Therapeutics currently has an average rating of “Buy” and an average target price of $14.60.

Insider Activity

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the completion of the transaction, the insider now directly owns 2,733,547 shares of the company’s stock, valued at approximately $5,658,442.29. The trade was a 67.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 8.87% of the company’s stock.

Black Diamond Therapeutics Stock Performance

Black Diamond Therapeutics stock opened at $1.39 on Friday. Black Diamond Therapeutics, Inc. has a fifty-two week low of $1.20 and a fifty-two week high of $7.66. The company has a market capitalization of $78.76 million, a PE ratio of -1.05 and a beta of 2.81. The company has a 50 day moving average price of $1.85 and a 200-day moving average price of $2.44.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. On average, analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.